The Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss

Exclusion Criteria

• •1. Females who are pregnant, breastfeeding or planning to become pregnant during the course of the study
• •2. Subjects who are smokers (tobacco, e-cigarettes) or have been a smoker within the past 1 year from screening
• •3. Individuals who carry an epi-pen, or those with a diagnosed allergy or who believe that they have an allergy to milk or milk products, crustacean shellfish, tree nuts, or peanuts
• •4. Individuals with a severe allergy to egg, fish, wheat or soy ingredients as the product is manufactured in a facility that contains these ingredients
• •5. The use of prescription, over-the-counter health products, or natural health products/dietary supplements being taken for weight loss, cholesterol levels, or blood pressure within 4 weeks of screening
• •6. Subjects with a history of eating disorders
• •7. Current participation or participation within the last 3 months in any weight loss program or diet (for example Weight Watchers, Jenny Craig, DASH diet, Atkins, Mediterranean etc.)
• •8. Medical history of thyroid disorders except for subjects diagnosed with hypothyroid and have been on stable medication for at least the last 3 months prior to enrollment. All subject with medical history of hyperthyroid are excluded
• •9. Medical history of hypercholesterolipidemia
• •10. Use of cholesterol lowering prescription drugs within the last 6 months
• •11. Fasting TGs ≥ 200 mg/dL (2.26 mmol/L) or a fasting total cholesterol ≥ 240 mg/dL (6.216 mmol/L)
• •12. Fasting glucose ≥ 126 mg/dL
• •13. Hypertension defined as untreated systolic blood pressure \>160 mmHg, diastolic blood pressure \>100 mmHg, or the use of prescription high blood pressure/hypertension medications within the last 6 months
• •14. Type I or Type II diabetes or use of diabetes medication in a preventative setting.
• •15. History of gastrointestinal dysfunction or surgery that may influence digestion or absorption
• •16. Chronic inflammation or structural abnormality, including history of, of the digestive tract (inflammatory bowel disease, celiac disease, chronic diarrhea, chronic constipation, duodenal or gastric ulcer, gastric retention or obstruction, Gastroesophageal reflux disease (GERD), or symptomatic cholelithiasis)
• •17. Subjects who have a history of colorectal cancer, bowel resection, rectocele, or colostomy
• •18. Immunocompromised individuals such as subjects that have undergone organ transplantation, those with rheumatoid arthritis, or subjects diagnosed with human immunodeficiency virus (HIV)
• •19. Unstable medical conditions that in the opinion of the Qualified Investigator preclude the subject from participating in the study
• •20. Anti-anxiety and anti-psychotic medications will be assessed by the MD on a case by case basis
• •21. Alcohol use \> 2 standard alcoholic drinks per day
• •22. Alcohol or drug abuse within the last 6 months
• •23. Use of medicinal marijuana
• •24. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative
• •25. Subjects with metal fixation plates or screws from a previous surgery
• •26. Clinically significant abnormal laboratory results at screening
• •27. Participation in a clinical research trial within 30 days prior to randomization
• •28. Allergy or sensitivity to study supplement ingredients
• •29. Individuals who are cognitively impaired and/or who are unable to give informed consent
• •30. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
• •31. Unwilling or unable to comply with study timeline and procedures
• •32. Individuals who do not like the taste of chocolate or shake type drinks